Share This Page:   

 

Browse by Clinical Topic:
Select a Topic to Learn More

Featured CME/CE Content:

 

neuroscienceCME Editors' Picks:

Complex Presentations of Sleep-Wake Dysfunction: Case Challenges, Part 6

neuroscienceCME Video Snack

Premiere Date: Monday, August 31, 2009

This activity offers CE credit for:

Physicians (ACCME/AMA PRA Category 1)
All other clinicians will receive a CME Attendance Certificate.
Credit Expiration Date:
Tuesday, August 31, 2010

Faculty

Thomas Roth, PhD (Moderator) Director, Sleep Disorders and Research Center Henry Ford Hospital Clinical Professor of Psychiatry University of Michigan School of Medicine Detroit, MI

Daniel J. Buysse, MD  Professor of Psychiatry and Clinical and Translational Science University of Pittsburgh School of Medicine Pittsburgh, PA

Phyllis C. Zee, MD, PhD  Professor of Neurology Director, Sleep Disorders Center Associate Director, Center for Sleep & Circadian Biology Northwestern University Feinberg School of Medicine Chicago, IL

Statement of Need

Sleep disorders and accompanying symptoms of excessive sleepiness not only negatively impact daily functioning, cognitive performance, personal relationships, quality of life, and mood, but also pose a danger to public safety when drowsy drivers get behind the wheel of an automobile. Sleep disorders have been associated with physiologic consequences such as increased insulin resistance, obesity, cardiovascular disease and diabetes. The presentations of sleep-wake disorders can be complex and varied, requiring clinicians to conduct a thorough clinical interview, utilize validated screening tools such as the Epworth Sleepiness Scale (ESS), recognize when a referral for a sleep study is appropriate, and develop a multimodal treatment plan to optimize outcomes. In this neuroscienceCME series, the faculty—who represent both the primary care and specialty perspective—will present real-world cases and provide insights and strategies to managing patients with sleep-wake disorders.

---

1. Thorpy MJ, Lieberman JA, Roth T, Owens GS. Patient-management strategies. Am J Manag Care 2007;13:S140-S147.

Activity Goal

To translate new evidence in the literature into improved treatment of sleep-wake disorders.

Learning Objectives

At the end of this CE activity, participants should be able to:

• Recognize the bidirectional relationship between sleep disorders and psychiatric disorders and their treatment.

Target Audience

Physicians, sleep specialists, physician assistants, and other healthcare professionals interested in sleep-wake disorders.

Financial Support

CME Outfitters, LLC, gratefully acknowledges an independent educational grant from Cephalon, Inc., in support of this CE activity.

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. CME Outfitters, LLC, designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Note to Physician Assistants: AAPA accepts Category I credit from AOACCME, Prescribed credit from AAFP, and AMA Category I CME credit for the PRA from organizations accredited by ACCME.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. The University of Texas Southwestern Medical Center and CME Outfitters, LLC, have evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Roth has disclosed that he receives grant support from Aventis, Cephalon, Inc., GlaxoSmithKline, Neurocrine Biosciences, Inc., Pfizer, Inc., Sanofi-aventis, Schering-Plough Corporation, Sepracor, Inc., Samaxon Pharmaceuticals, Inc., Syrex, Takeda Pharmaceuticals North America, Inc., TransOral Pharmaceuticals, Inc., Wyeth Pharmaceuticals, and XenoPort, Inc. He serves as a consultant to Abbott Laboratories, Acadia Pharmaceuticals Inc., Acoglix, Acorda Therapeutics, Actelion, Addrenex Pharmaceuticals, Inc., Alchemers, ALZA Corporation, Ancil, Arena Pharmaceuticals, AstraZeneca Pharmaceuticals LP, Aventis, AVER, Bayer, Bristol-Myers Squibb Company, BTG, Cephalon, Inc., Cypress Pharmaceutical, Inc., Dove Pharmaceuticals, Eisai Pharmaceuticals, Elan Pharmaceuticals, Inc., Eli Lilly and Company, Evotec Inc., Forest Laboratories, Inc., GlaxoSmithKline, Hypnion Inc., IMPAX Laboratories, Inc., Intec Pharma, Intra-Cellular, Jazz Pharmaceuticals, Johnson & Johnson Pharmaceutical Research & Development, L.L.C., King Pharmaceuticals, Inc.; H. Lundbeck A/S; McNeil; MediciNova, Inc.; Merck & Co., Inc.; Neurim Pharmaceuticals; Neurocrine Biosciences, Inc.; Neurogen Corporation, Novartis Pharmaceuticals Corporation, Orexo AB, Organon International, Otsuka America Pharmaceutical, Inc., Prestwick Pharmaceuticals, Inc., Proctor & Gamble, Pfizer, Inc., Purdue Pharma L.P., Resteva, Roche, Sanofi-aventis, Schering-Plough Corporation, Sepracor, Inc., Servier, Shire Pharmaceuticals, Somaxon Pharmaceuticals, Inc., Syrex, Takeda Pharmaceuticals North America, Inc., TransOral Pharmaceuticals, Inc., VANDA Pharmaceuticals, VivoMetrics, Wyeth Pharmaceuticals, Yamanouchi Pharma America, Inc., and XenoPort, Inc. He is on the speakers bureau for Cephalon, Inc., Sanofi-aventis, and Takeda Pharmaceuticals North America, Inc.

Dr. Buysse has disclosed that he receives grant support from Sepracor, Inc. He serves as a consultant to Actelion, Arena Pharmaceuticals, Cephalon, Inc., Eli Lilly and Company, GlaxoSmithKline, Merck & Co., Inc., Neurocrine Biosciences, Inc., Neurogen Corporation, Pfizer Inc., Sanofi-aventis, Sepracor, Inc,; Servier, Somnus Therapeutics, Stress Eraser, Takeda Pharmaceuticals North America, Inc., and Transcept Pharmaceuticals, Inc.

Dr. Zee has disclosed that she receives grant support from and is on the speakers bureau for Takeda Pharmaceuticals North America, Inc. She serves as a consultant to Cephalon, Inc., Philips, Sanofi-aventis, and Takeda Pharmaceuticals North America, Inc. She is a stock shareholder of Teva Pharmaceuticals USA.

Unlabeled Use Disclosure

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

CME Outfitters, LLC, the faculty, and Cephalon, Inc., do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).